BioRestorative Therapies (OTCMKTS:BRTXQ) Stock Price Down 4.5% - Here's What Happened

Key Points

• Down 4.5%: BioRestorative Therapies (OTCMKTS:BRTXQ) fell to $0.2960 intraday (low $0.2894) with about 1.58 million shares traded, a roughly 97% decline versus its reported average daily volume of 62.17 million shares.
• Technical and valuation metrics show the stock below key levels — 50‑day SMA $0.56 and 200‑day SMA $1.07 — with a market capitalization of $485.33 million, a negative P/E (-0.28) and an unusually high beta (102.36).
• Business focus: BioRestorative is a clinical‑stage regenerative medicine company through its subsidiary TissueForm, developing the TissueForm® micro‑fiber scaffold platform for chronic, non‑healing wounds such as diabetic foot ulcers.

BioRestorative Therapies, Inc. (OTCMKTS:BRTXQ - Get Free Report) dropped 4.5% during mid-day trading on Friday . The company traded as low as $0.2894 and last traded at $0.2960. Approximately 1,578,483 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 62,169,492 shares. The stock had previously closed at $0.31.

BioRestorative Therapies Stock Down 4.5%

The company's 50-day simple moving average is $0.56 and its 200 day simple moving average is $1.07. The company has a market capitalization of $485.33 million, a P/E ratio of -0.28 and a beta of 102.36.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc is a clinical‐stage regenerative medicine company focused on developing and commercializing advanced therapeutic platforms to promote tissue repair and healing. The company's principal business activities are conducted through its wholly owned subsidiary, TissueForm, Inc, which holds the rights to a proprietary micro‐fiber scaffold technology designed to create a three‐dimensional matrix supporting cell migration, proliferation and new tissue formation. BioRestorative's work is primarily targeted at chronic and non‐healing wounds, including diabetic foot ulcers and other complex soft‐tissue injuries.

The cornerstone of BioRestorative's product pipeline is the TissueForm® line of scaffold materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.